Craig-Hallum Sticks to Their Buy Rating for Clover Health Investments (CLOV)

In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Clover Health Investments (CLOV – Research Report), with a price target of $6.00.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Hewitt covers the Healthcare sector, focusing on stocks such as NeoGenomics, Clover Health Investments, and Apyx Medical. According to TipRanks, Hewitt has an average return of -5.3% and a 41.83% success rate on recommended stocks.

In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $4.50 price target.

The company has a one-year high of $4.87 and a one-year low of $0.79. Currently, Clover Health Investments has an average volume of 5.58M.

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CLOV in relation to earlier this year. Most recently, in March 2025, Carladenise Armbrister Edwards, a Director at CLOV sold 200,000.00 shares for a total of $722,000.00.